Novartis Institutes For Biomedical Research, Inc. - Net Worth and Insider Trading
Novartis Institutes For Biomedical Research, Inc. Net Worth
The estimated net worth of Novartis Institutes For Biomedical Research, Inc. is at least $73 Million dollars as of 2024-11-13. Novartis Institutes For Biomedical Research, Inc. is the 10% Owner of Intellia Therapeutics Inc and owns about 4,129,903 shares of Intellia Therapeutics Inc (NTLA) stock worth over $69 Million. Novartis Institutes For Biomedical Research, Inc. is also the 10% Owner of Surface Oncology Inc and owns about 3,948,482 shares of Surface Oncology Inc (SURF) stock worth over $4 Million. Details can be seen in Novartis Institutes For Biomedical Research, Inc.'s Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Novartis Institutes For Biomedical Research, Inc. has not made any transactions after 2018-04-23 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Novartis Institutes For Biomedical Research, Inc.
Novartis Institutes For Biomedical Research, Inc. Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Novartis Institutes For Biomedical Research, Inc. owns 3 companies in total, including Intellia Therapeutics Inc (NTLA) , Surface Oncology Inc (SURF) , and Homology Medicines Inc (FIXX) .
Insider Ownership Summary of Novartis Institutes For Biomedical Research, Inc.
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| NTLA | Intellia Therapeutics Inc | 2018-12-31 | 10 percent owner |
| SURF | Surface Oncology Inc | 2018-04-23 | 10 percent owner |
| FIXX | Homology Medicines Inc | 2018-03-27 | 10 percent owner |
Novartis Institutes For Biomedical Research, Inc. Latest Holdings Summary
Novartis Institutes For Biomedical Research, Inc. currently owns a total of 2 stocks. Among these stocks, Novartis Institutes For Biomedical Research, Inc. owns 4,129,903 shares of Intellia Therapeutics Inc (NTLA) as of December 12, 2017, with a value of $69 Million and a weighting of 94.21%. Novartis Institutes For Biomedical Research, Inc. also owns 3,948,482 shares of Surface Oncology Inc (SURF) as of April 23, 2018, with a value of $4 Million and a weighting of 5.79%.
Latest Holdings of Novartis Institutes For Biomedical Research, Inc.
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| NTLA | Intellia Therapeutics Inc | 2017-12-12 | 4,129,903 | 16.65 | 68,762,885 |
| SURF | Surface Oncology Inc | 2018-04-23 | 3,948,482 | 1.07 | 4,224,876 |
Holding Weightings of Novartis Institutes For Biomedical Research, Inc.
Novartis Institutes For Biomedical Research, Inc. Form 4 Trading Tracker
According to the SEC Form 4 filings, Novartis Institutes For Biomedical Research, Inc. has made a total of 0 transactions in Intellia Therapeutics Inc (NTLA) over the past 5 years. The most-recent trade in Intellia Therapeutics Inc is the sale of 1,523,000 shares on December 12, 2017, which brought Novartis Institutes For Biomedical Research, Inc. around $28 Million.
According to the SEC Form 4 filings, Novartis Institutes For Biomedical Research, Inc. has made a total of 0 transactions in Surface Oncology Inc (SURF) over the past 5 years. The most-recent trade in Surface Oncology Inc is the acquisition of 766,666 shares on April 23, 2018, which cost Novartis Institutes For Biomedical Research, Inc. around $12 Million.
Insider Trading History of Novartis Institutes For Biomedical Research, Inc.
- 1
Novartis Institutes For Biomedical Research, Inc. Trading Performance
GuruFocus tracks the stock performance after each of Novartis Institutes For Biomedical Research, Inc.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Novartis Institutes For Biomedical Research, Inc. is -11.01%. GuruFocus also compares Novartis Institutes For Biomedical Research, Inc.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Novartis Institutes For Biomedical Research, Inc. within 3 months outperforms 1 times out of 2 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Novartis Institutes For Biomedical Research, Inc.'s insider trading performs compared to the benchmark.
Performance of Novartis Institutes For Biomedical Research, Inc.
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 12.01 | | | | | |
| Relative Return to S&P 500(%) | 10.07 | | | | | |
Novartis Institutes For Biomedical Research, Inc. Ownership Network
Ownership Network List of Novartis Institutes For Biomedical Research, Inc.
Ownership Network Relation of Novartis Institutes For Biomedical Research, Inc.
Novartis Institutes For Biomedical Research, Inc. Owned Company Details
What does Intellia Therapeutics Inc do?
Who are the key executives at Intellia Therapeutics Inc?
Novartis Institutes For Biomedical Research, Inc. is the 10 percent owner of Intellia Therapeutics Inc. Other key executives at Intellia Therapeutics Inc include EVP & Chief Technical Officer Eliana Clark , EVP & Chief Scientific Officer Laura Sepp-lorenzino , and EVP & Chief Business Officer Derek Hicks .
Intellia Therapeutics Inc (NTLA) Insider Trades Summary
Over the past 18 months, Novartis Institutes For Biomedical Research, Inc. made no insider transaction in Intellia Therapeutics Inc (NTLA). Other recent insider transactions involving Intellia Therapeutics Inc (NTLA) include a net sale of 10,373 shares made by Eliana Clark , a net sale of 2,397 shares made by Muna Bhanji , and a net sale of 7,807 shares made by Laura Sepp-lorenzino .
In summary, during the past 3 months, insiders sold 2,012 shares of Intellia Therapeutics Inc (NTLA) in total and bought 0 shares, with a net sale of 2,012 shares. During the past 18 months, 62,207 shares of Intellia Therapeutics Inc (NTLA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 62,207 shares.
Intellia Therapeutics Inc (NTLA)'s detailed insider trading history can be found in Insider Trading Tracker table.
Intellia Therapeutics Inc Insider Transactions
Novartis Institutes For Biomedical Research, Inc. Mailing Address
Above is the net worth, insider trading, and ownership report for Novartis Institutes For Biomedical Research, Inc.. You might contact Novartis Institutes For Biomedical Research, Inc. via mailing address: 250 Massachusetts Avenue, Cambridge Ma 02139.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
